University of Illinois at Chicago
Browse

HMGB1: A Promising Therapeutic Target for Prostate Cancer

Download (1.38 MB)
journal contribution
posted on 2014-01-09, 00:00 authored by Munirathinam Gnanasekar, Ramaswamy Kalyanasundaram, Guoxing Zheng, Aoshuang Chen, Maarten C. Bosland, André Kajdacsy-Balla
High mobility group box 1 (HMGB1) was originally discovered as a chromatin-binding protein several decades ago. It is now increasingly evident that HMGB1 plays a major role in several disease conditions such as atherosclerosis, diabetes, arthritis, sepsis, and cancer. It is intriguing how deregulation of HMGB1 can result in a myriad of disease conditions. Interestingly, HMGB1 is involved in cell proliferation, angiogenesis, and metastasis during cancer progression. Furthermore, HMGB1 has been demonstrated to exert intracellular and extracellular functions, activating key oncogenic signaling pathways. This paper focuses on the role of HMGB1 in prostate cancer development and highlights the potential of HMGB1 to serve as a key target for prostate cancer treatment.

History

Publisher Statement

Copyright © 2013 Munirathinam Gnanasekar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This is a copy of an article published in the Prostate Cancer © 2013 Hindawi Publishing Corporation

Publisher

Hindawi Publishing Corporation

Language

  • en_US

issn

2090-3111

Issue date

2013-05-01

Usage metrics

    Categories

    No categories selected

    Keywords

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC